Erasca Inc
ERASHealthcare·Biotechnology·USA·Mid·NASD·Nov 13 • 7:18 AM ET
15.79+0.01 (0.05%)
2026-11-13 13:39 CET
Market cap
$5.52B
Revenue, TTM
0.00 USD m
Net income, TTM
-307.94 USD m
Free cash flow, TTM
-109.24 USD m
EPS diluted, TTM
-1.00
Price
ERAS against its 20, 50 and 200-day averagesPatternshover a marker to name it
35.0% under the 52-week high of 24.28 on 23 Apr 2026. 52-week low 2.46 on 13 Nov 2025. Last 15 sessions, 32.3% high to low
Volume 0.01× normal · the line is the 50-bar volume average
Setup. RS line 70
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 4 of 6 — fails: 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 2 of 4 — fails: 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Zanger 2 of 5 — fails: Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 4 of 5 — fails: 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: Float: Under 100M
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 3 of 3
Profile
ERAS52-week range, 61% of the way up
2.4624.28
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
| Index | RUT |
|---|---|
| Employees | 103 |
| IPO | Jul 16, 2021 |
| Beta | 0.64 |
| ATR, 14d | 1.20 |
| Rel volume | 0.01 |
| Short float | 15.03% |
| Insider own | 29.33% |
| Inst own | 62.42% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $5.52B |
| Enterprise Value | 4.92B |
| Income | -307.94M |
| Sales | 0.00M |
| Book / share | 2.62 |
| Cash / share | 1.84 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 103 |
| IPO | Jul 16, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 6.03 |
| Price / cash | 8.58 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 14.89 |
| Current Ratio | 14.89 |
| Debt / equity | 0.05 |
| Long-term debt / equity | 0.04 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.00 |
|---|---|
| Earnings next year | -0.70 |
| Earnings next quarter | -0.15 |
| Earnings this year | -127.01% |
| Earnings next year | 29.56% |
| Earnings growth, 5 years | -26.76% |
| Past earnings growth | 39.56% 12.46% |
| Past sales growth | - - |
| Earnings vs last year | -110.63% |
| Sales vs last year | - |
| Earnings vs last quarter | -38.18% |
| Sales vs last quarter | - |
| Earnings | Nov 12 AMC |
| Surprise | -15.30% - |
Ownership
| Insiders own | 29.33% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 62.42% |
| Institution trades | 2.11% |
| Return on assets | -43.39% |
| Return on equity | -48.70% |
| Return on capital | -32.26% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 6.47% |
| 50-day average | 5.54% |
| 200-day average | 3.48% |
Technical
| Shares out | 350.24M |
|---|---|
| Shares floating | 247.18M |
| Short / float | 15.03% |
| Short ratio | 7.86 |
| Short interest | 37.16M |
| 52-week high | 24.28 -35.0% |
| 52-week low | 2.46 +541.8% |
| Volatility | 8.88% 8.05% |
| Average range | 1.20 |
| Strength index | 54.64 |
| Market sensitivity | 0.64 |
| Relative volume | 0.01 |
| Avg Volume | 4.73M |
| Volume | 2,055 |
Performance
| Perf Week | 9.56% |
|---|---|
| Perf Month | 6.17% |
| Perf Quarter | -13.63% |
| Perf Half Y | 54.33% |
| Perf YTD | 324.41% |
| Perf Year | 521.57% |
| Perf 3Y | 713.81% |
| Perf 5Y | -18.83% |
| Perf 10Y | - |
| Recommendation | 1.40 |
| Target Price | 23.70 |
| Prev Close | 15.78 |
| Price | 15.79 |
| Change % | 0.05% |
Analyst ratings
latest 10 of 14| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jun 04, 2026 | Upgrade | BofA Securities | Underperform → Neutral | $16 | +1.3% |
| Jan 27, 2026 | Resumed | Mizuho | Outperform | $16 | +1.3% |
| Jan 07, 2026 | Initiated | Piper Sandler | Overweight | $5 | -68.3% |
| Oct 16, 2025 | Initiated | Stifel | Buy | $4 | -74.7% |
| Sep 03, 2025 | Downgrade | BofA Securities | Buy → Underperform | ||
| Aug 18, 2025 | Downgrade | Morgan Stanley | Overweight → Equal-Weight | $2 | -87.3% |
| Mar 26, 2025 | Initiated | Raymond James | Outperform | $5 | -68.3% |
| Nov 18, 2024 | Initiated | Jefferies | Buy | $6 | -62.0% |
| Mar 11, 2024 | Initiated | CapitalOne | Overweight | $8 | -49.3% |
| Jan 05, 2024 | Downgrade | BofA Securities | Buy → Neutral | $11 → $6 | -62.0% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| RVMD | Revolution Medicines Inc | 38.12B |
| BBOT | BridgeBio Oncology Therapeutics Inc | 188.59M |
| VSTM | Verastem Inc | 1.05B |
| TNGX | Tango Therapeutics Inc | 4.21B |
| IMRX | Immuneering Corp | 240.98M |
| IDYA | Ideaya Biosciences Inc | 3.04B |
| RLAY | Relay Therapeutics Inc | 4.00B |
| COGT | Cogent Biosciences Inc | 4.87B |
| AMGN | AMGEN Inc | 252.64B |
| BMY | Bristol-Myers Squibb Co | 127.42B |
Insider trading
latest 14 of 21| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Erasca Foundation | Foundation | Oct 15 '26 | Proposed Sale | 14.68 | 8,333 | 122,353 | Oct 15 12:18 PM | |
| Erasca Foundation | Foundation | Sep 15 '26 | Proposed Sale | 15.97 | 8,333 | 133,094 | Sep 15 04:46 PM | |
| Erasca Foundation | Foundation | Aug 17 '26 | Proposed Sale | 18.29 | 8,333 | 152,419 | Aug 17 02:13 PM | |
| Erasca Foundation | Foundation | Jul 21 '26 | Proposed Sale | 18.92 | 8,333 | 157,638 | Jul 21 04:05 PM | |
| Erasca Foundation | Foundation | Jun 15 '26 | Proposed Sale | 14.10 | 8,333 | 117,477 | Jun 15 05:52 PM | |
| Erasca Foundation | Foundation | May 15 '26 | Proposed Sale | 10.14 | 8,333 | 84,528 | May 15 04:46 PM | |
| Erasca Foundation | Foundation | Apr 15 '26 | Proposed Sale | 18.10 | 8,333 | 150,843 | Apr 15 05:06 PM | |
| Garner Ebun | Chief Legal Officer | Apr 01 '26 | Option Exercise | 1.70 | 80,000 | 136,000 | 105,076 | Apr 03 09:00 AM |
| Garner Ebun | Chief Legal Officer | Apr 01 '26 | Sale | 16.40 | 80,000 | 1,312,000 | 25,076 | Apr 03 09:00 AM |
| Ebun Garner | Officer | Apr 01 '26 | Proposed Sale | 16.40 | 80,000 | 1,312,355 | Apr 01 02:19 PM | |
| Erasca Foundation | Foundation | Mar 16 '26 | Proposed Sale | 14.02 | 8,333 | 116,855 | Mar 16 02:38 PM | |
| Morris Shannon | Chief Medical Officer | Mar 04 '26 | Option Exercise | 1.70 | 20,000 | 34,000 | 20,000 | Mar 06 09:00 AM |
| Morris Shannon | Chief Medical Officer | Mar 04 '26 | Sale | 15.04 | 20,000 | 300,760 | 0 | Mar 06 09:00 AM |
| Shannon Morris | Officer | Mar 04 '26 | Proposed Sale | 15.04 | 20,000 | 300,769 | Mar 04 05:38 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 80.23B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| VBR | Vanguard Morningstar Small-Cap Value ETF | AUM: 37.88B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
News
latest 14 of 200- Erasca Reports Third Quarter 2026 Business Updates and Financial Results (GlobeNewswire) -6.07%
- Erasca to Present at Upcoming Conferences in November (GlobeNewswire)
- Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium (GlobeNewswire)
- Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
- Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma (GlobeNewswire)
- Erasca Reports Second Quarter 2026 Business Updates and Financial Results (GlobeNewswire)
- Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D (GlobeNewswire)
- Kaplan Fox Encourages Erasca, Inc. (ERAS) Investors with Losses to Contact the Firm Before August 10, 2026 (Newsfile)
- Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026 (Newsfile)
- ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses (Newsfile)
- Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS (PR Newswire)
- Kaplan Fox Encourages Investors of Erasca, Inc. (ERAS) Who Suffered Losses to Contact the Firm Before August 10, 2026 (Newsfile)
- Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +9.03% -10.54%
Quarterly earnings
2026Q3 EPS -0.150 missed -0.130, from -0.110 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-12 16:30 | -0.150 | -0.130 | -0.130 | 0.00 | 0.00 | EPS +15.3% · sales - | vs 2025Q3, year-ago quarter · EPS +36.4% · sales - | 10 EPS · 7 sales | Open -6.21% vs SPY -0.14%. Close +0.05% vs SPY +0.24% |
| 2026Q2ended 2026-06-30 | 2026-08-11 16:30 | -0.140 | -0.111 | -0.142 | 0.00 | 0.00 | EPS +25.7% · sales - | vs 2025Q2, year-ago quarter · EPS +16.7% · sales - | 10 EPS · 7 sales | Open +0.66% vs SPY +0.54%. Close +1.47% vs SPY +0.25% |
| 2026Q1ended 2026-03-31 | 2026-05-11 16:30 | -0.600 | -0.104 | -0.603 | 0.00 | 0.00 | EPS +475.3% · sales - | vs 2025Q1, year-ago quarter · EPS +445.5% · sales - | 8 EPS · 6 sales | Open -2.11% vs SPY -0.33%. Close -0.57% vs SPY -0.15% |
| 2025Q4ended 2025-12-31 | 2026-03-12 16:30 | -0.100 | -0.107 | -0.103 | 0.00 | 0.00 | EPS -6.5% · sales - | vs 2024Q4, year-ago quarter · EPS -9.1% · sales - | 10 EPS · 7 sales | Open +3.41% vs SPY +0.48%. Close -7.03% vs SPY -0.57% |
| 2025Q3ended 2025-09-30 | 2025-11-12 16:30 | -0.110 | -0.104 | -0.108 | 0.00 | 0.00 | EPS +6.3% · sales - | vs 2024Q3, year-ago quarter · EPS 0.0% · sales - | 9 EPS · 6 sales | Open 0.00% vs SPY -0.42%. Close -4.15% vs SPY -1.66% |
| 2025Q2ended 2025-06-30 | 2025-08-12 16:30 | -0.120 | -0.116 | -0.120 | 0.00 | 0.00 | EPS +3.9% · sales - | vs 2024Q2, year-ago quarter · EPS -58.6% · sales - | 6 EPS · 4 sales | Open -0.64% vs SPY +0.35%. Close +3.85% vs SPY +0.34% |
| 2025Q1ended 2025-03-31 | 2025-05-13 16:30 | -0.110 | -0.124 | -0.109 | 0.00 | 0.00 | EPS -11.6% · sales - | vs 2024Q1, year-ago quarter · EPS -52.2% · sales - | 6 EPS · 3 sales | Open +2.26% vs SPY +0.17%. Close -4.51% vs SPY +0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-20 16:30 | -0.110 | -0.125 | -0.114 | 0.00 | 0.00 | EPS -11.8% · sales - | vs 2023Q4, year-ago quarter · EPS -45.0% · sales - | 7 EPS · 3 sales | Open 0.00% vs SPY -1.10%. Close +3.38% vs SPY -0.27% |
| 2024Q3ended 2024-09-30 | 2024-11-12 16:30 | -0.110 | -0.167 | -0.111 | 0.00 | 0.00 | EPS -34.2% · sales - | vs 2023Q3, year-ago quarter · EPS -45.0% · sales - | 6 EPS · 4 sales | Open +2.34% vs SPY +0.08%. Close -4.68% vs SPY +0.05% |
| 2024Q2ended 2024-06-30 | 2024-08-12 16:30 | -0.290 | -0.183 | -0.290 | 0.00 | 0.00 | EPS +58.5% · sales - | vs 2023Q2, year-ago quarter · EPS +38.1% · sales - | 7 EPS · 4 sales | Open +4.25% vs SPY +0.61%. Close +0.39% vs SPY +1.64% |
| 2024Q1ended 2024-03-31 | 2024-05-08 16:30 | -0.230 | -0.202 | -0.232 | 0.00 | 0.00 | EPS +14.1% · sales - | vs 2023Q1, year-ago quarter · EPS +4.5% · sales - | 7 EPS · 4 sales | Open -0.47% vs SPY +0.04%. Close -8.84% vs SPY +0.58% |
| 2023Q4ended 2023-12-31 | 2024-03-27 16:30 | -0.200 | -0.227 | -0.197 | 0.00 | 0.00 | EPS -11.7% · sales - | vs 2022Q4, year-ago quarter · EPS -81.1% · sales - | 7 EPS · 4 sales | Open +17.48% vs SPY +0.01%. Close 0.00% vs SPY -0.02% |
| 2023Q3ended 2023-09-30 | 2023-11-09 16:30 | -0.200 | -0.230 | -0.202 | 0.00 | 0.00 | EPS -13.0% · sales - | vs 2022Q3, year-ago quarter · EPS -31.0% · sales - | 7 EPS · 5 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-10 16:30 | -0.210 | -0.252 | -0.212 | 0.00 | 0.00 | EPS -16.6% · sales - | vs 2022Q2, year-ago quarter · EPS -30.0% · sales - | 6 EPS · 3 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-15 16:30 | -0.220 | -0.325 | -0.222 | 0.00 | 0.00 | EPS -32.4% · sales - | vs 2022Q1, year-ago quarter · EPS -29.0% · sales - | 4 EPS · 3 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-23 16:30 | -1.060 | -0.398 | -1.060 | 0.00 | 0.00 | EPS +166.3% · sales - | vs 2021Q4, year-ago quarter · EPS +307.7% · sales - | 6 EPS · 4 sales | - |
Annual earnings
2025FY EPS -0.440 beat -0.444, from -0.690 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.433 | - | - | 353.94 | - |
| 2029FYestimate | - | -0.938 | - | - | 41.49 | - |
| 2028FYestimate | - | -0.896 | - | - | 0.00 | - |
| 2027FYestimate | - | -0.704 | - | - | 0.00 | - |
| 2026FYestimate | - | -0.999 | - | - | 0.00 | - |
| 2025FY | -0.440 | -0.444 | -0.440 | 0.00 | 0.00 | - |
| 2024FY | -0.690 | -0.729 | -0.691 | 0.00 | 0.00 | - |
| 2023FY | -0.830 | -0.912 | -0.833 | 0.00 | 0.00 | - |
| 2022FY | -1.990 | -1.304 | -1.990 | 0.00 | 0.00 | - |
| 2021FY | -1.850 | -2.222 | -1.031 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.00 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-13 | -1.00 | +2.6% |
| 2026Q4 | E | per share | 2026-11-13 | -0.15 | +9.8% |
| 2026Q4 | R | per share | 2026-11-13 | -0.15 | 0.0% |
| 2026Q4 | S | per share | 2026-11-13 | 0.00 | - |
| 2026Q3 | R | per share | 2026-11-09 | -0.13 | 0.0% |
| 2026Q3 | E | per share | 2026-11-02 | -0.13 | 0.0% |
| 2026FY | R | per share | 2026-11-02 | -1.00 | 0.0% |
| 2026FY | S | per share | 2026-09-04 | 0.00 | - |
| 2026Q3 | S | per share | 2026-09-04 | 0.00 | - |
| 2026Q2 | E | per share | 2026-07-28 | -0.11 | 0.0% |
| 2026Q2 | R | per share | 2026-07-26 | -0.12 | 0.0% |
| 2026Q2 | S | per share | 2026-07-10 | 0.00 | - |
| 2026Q1 | E | per share | 2026-03-17 | -0.10 | -0.7% |
| 2026Q1 | R | per share | 2026-03-17 | -0.10 | -4.7% |
| 2026Q1 | S | per share | 2026-03-13 | 0.00 | - |
| 2025FY | E | per share | 2026-03-06 | -0.44 | +0.0% |
| 2025Q4 | E | per share | 2026-03-06 | -0.11 | -0.1% |
| 2025FY | R | per share | 2026-03-06 | -0.44 | +0.2% |
| 2025Q4 | R | per share | 2026-03-06 | -0.11 | -0.2% |
| 2025FY | S | per share | 2026-03-06 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-06 | 0.00 | - |
| 2025Q3 | E | per share | 2025-10-27 | -0.10 | 0.0% |
| 2025Q3 | R | per share | 2025-10-27 | -0.11 | 0.0% |
| 2025Q3 | S | per share | 2025-10-14 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-06 | -0.12 | 0.0% |
| 2025Q2 | R | per share | 2025-08-06 | -0.12 | 0.0% |
| 2025Q2 | S | per share | 2025-07-25 | 0.00 | - |
| 2025Q1 | E | per share | 2025-05-07 | -0.12 | +1.6% |
| 2025Q1 | R | per share | 2025-05-07 | -0.12 | +2.4% |
| 2025Q1 | S | per share | 2025-05-07 | 0.00 | - |
| 2024FY | E | per share | 2025-02-02 | -0.73 | 0.0% |
| 2024Q4 | E | per share | 2025-02-02 | -0.12 | 0.0% |
| 2024FY | R | per share | 2025-02-02 | -0.74 | 0.0% |
| 2024Q4 | R | per share | 2025-02-02 | -0.11 | 0.0% |
| 2024FY | S | per share | 2025-02-01 | 0.00 | - |
| 2024Q4 | S | per share | 2025-02-01 | 0.00 | - |
| 2024Q3 | E | per share | 2024-11-02 | -0.17 | 0.0% |
| 2024Q3 | R | per share | 2024-10-31 | -0.17 | -9.8% |
| 2024Q3 | S | per share | 2024-08-13 | 0.00 | - |
| 2024Q2 | E | per share | 2024-07-31 | -0.18 | 0.0% |
| 2024Q2 | R | per share | 2024-07-31 | -0.19 | 0.0% |
| 2024Q2 | S | per share | 2024-05-09 | 0.00 | - |
| 2024Q1 | E | per share | 2024-04-24 | -0.20 | 0.0% |
| 2024Q1 | R | per share | 2024-04-15 | -0.21 | -12.2% |
| 2024Q1 | S | per share | 2024-03-29 | 0.00 | - |
| 2023FY | E | per share | 2024-03-08 | -0.91 | +0.5% |
| 2023FY | R | per share | 2024-03-08 | -1.02 | -3.9% |
| 2023FY | S | per share | 2024-01-11 | 0.00 | - |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.101 | -0.855 | -1.031 | -1.99 | -0.833 | -0.691 | -0.439 | -0.996 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 119 | 119 | 119 | 149 | 151 | 283 | 284 | - | 350 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.111 | -0.114 | -0.109 | -0.12 | -0.108 | -0.103 | -0.603 | -0.142 | -0.149 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 283 | 283 | 283 | 284 | 284 | 284 | 311 | 313 | 350 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 2.89 | 3.11-18.4% | 3.81+2.1% | 3.73+41.3% | 2.64+218.1% | 0.83+53.7% | 0.54+74.2% | 0.31 |
| Gross Profit | -2.89 | -3.11 | -3.81 | -3.73 | -2.64 | -0.83 | -0.54 | -0.31 |
| Selling, General and Administrative Excl. Other | 174.76 | 128.30-13.7% | 148.63+7.9% | 137.79-43.7% | 244.81+97.3% | 124.05+14.1% | 108.71+737.5% | 12.98 |
| Research and Development | 133.60 | 92.85-17.4% | 112.41+8.3% | 103.82-51.6% | 214.46+153.0% | 84.77-16.3% | 101.30+953.0% | 9.62 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -177.66 | -131.41 | -152.43 | -141.53 | -247.45 | -124.88 | -109.25 | -13.29 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 150.00 | 9.50-65.0% | 27.15 | 0.00 | 0.00 | -1.61 | -7.36 | 0.00 |
| Net Income Before Taxes | -307.94 | -124.55 | -161.65 | -125.04 | -242.81 | -122.76 | -101.66 | -12.04 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -307.94 | -124.55 | -161.65 | -125.04 | -242.81 | -122.76 | -101.66 | -12.04 |
| Net Income From Continuing Operations | -307.94 | -124.55 | -161.65 | -125.04 | -242.81 | -122.76 | -101.66 | -12.04 |
| Net Income | -307.94 | -124.55 | -161.65 | -125.04 | -242.81 | -122.76 | -101.66 | -12.04 |
| EPS (Recurring) per share | -0.59 | -0.42 | -0.61 | -0.83 | -1.99 | -1.04 | -0.90 | -0.10 |
| EPS (Basic, Before Extraordinaries) per share | -1.00 | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| EPS (Diluted) per share | -1.00 | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| EBITDA | -174.76 | -128.30 | -148.63 | -137.79 | -244.81 | -124.05 | -108.71 | -12.98 |
| Non-Operating Income (Expense) | 19.71 | 16.36-8.8% | 17.94+8.9% | 16.48+255.2% | 4.64+828.0% | 0.50+117.4% | 0.23-81.6% | 1.25 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 35.82 | 24.90-7.7% | 26.97+2.8% | 26.23+30.4% | 20.11+141.4% | 8.33+941.3% | 0.80+566.7% | 0.12 |
| Shares Outstanding million shares | 350.24 | 284.16+0.3% | 283.22+87.5% | 151.09+1.2% | 149.33+25.4% | 119.10+0.1% | 118.960.0% | 118.96 |
| Market Capitalization | 5,519.24 | 5,519.24+677.8% | 709.64+120.5% | 321.82-45.8% | 593.69-68.6% | 1,889.08+3.0% | 1,833.30 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.71-6.6% | 0.72-8.9% | 0.72-12.2% | 0.74-10.8% | 0.76-9.5% | 0.79-28.2% | 0.82-18.0% | 0.83-11.7% |
| Gross Profit | -0.71 | -0.72 | -0.72 | -0.74 | -0.76 | -0.79 | -0.82 | -0.83 |
| Selling, General and Administrative Excl. Other | 58.81+85.0% | 46.90+57.2% | 37.19+6.8% | 31.86-8.7% | 31.79-12.7% | 29.84-32.5% | 34.81-8.0% | 34.88+5.9% |
| Research and Development | 47.20+110.1% | 35.90+69.6% | 27.27+5.0% | 23.24-11.0% | 22.47-18.7% | 21.17-35.9% | 25.97-9.1% | 26.12+5.3% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -59.52 | -47.62 | -37.91 | -32.60 | -32.55 | -30.62 | -35.63 | -35.71 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00-100.0% | 0.00-100.0% | 150.00 | 0.00 | 2.00 | 7.50-66.7% | 0.00 | 0.00 |
| Net Income Before Taxes | -51.33 | -44.08 | -183.44 | -29.09 | -30.61 | -33.88 | -30.97 | -32.23 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -51.33 | -44.08 | -183.44 | -29.09 | -30.61 | -33.88 | -30.97 | -32.23 |
| Net Income From Continuing Operations | -51.33 | -44.08 | -183.44 | -29.09 | -30.61 | -33.88 | -30.97 | -32.23 |
| Net Income | -51.33 | -44.08 | -183.44 | -29.09 | -30.61 | -33.88 | -30.97 | -32.23 |
| EPS (Recurring) per share | -0.15 | -0.14 | -0.26 | -0.10 | -0.10 | -0.10 | -0.11 | -0.11 |
| EPS (Basic, Before Extraordinaries) per share | -0.15 | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.11 |
| EPS (Diluted) per share | -0.15 | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.11 |
| EBITDA | -58.81 | -46.90 | -37.19 | -31.86 | -31.79 | -29.84 | -34.81 | -34.88 |
| Non-Operating Income (Expense) | 8.19+108.4% | 3.54-16.7% | 4.47-4.1% | 3.51+0.9% | 3.93-34.9% | 4.25-7.2% | 4.66+21.7% | 3.48-16.5% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 11.93+100.2% | 9.61+50.2% | 8.46+26.1% | 5.82-7.8% | 5.96-10.2% | 6.40-10.9% | 6.71-2.0% | 6.31+2.8% |
| Shares Outstanding million shares | 350.24+23.5% | 312.56+10.2% | 310.81+9.7% | 284.16+0.3% | 283.71+0.4% | 283.65+3.9% | 283.27+87.3% | 283.22+87.5% |
| Market Capitalization | 5,519.24+792.5% | 5,697.25+1483.6% | 5,028.74+1195.8% | 1,055.41+48.7% | 618.40-19.8% | 359.77-41.3% | 388.07+24.7% | 709.64+120.5% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 276.07-7.5% | 298.31-4.5% | 312.35-28.3% | 435.62+5.1% | 414.48+249.2% | 118.70+135.7% | 50.37 |
| Short Term Receivables | 2.50+8.7% | 2.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 7.66-6.4% | 8.18-1.8% | 8.33-6.2% | 8.88+60.3% | 5.54+329.5% | 1.29+72.0% | 0.75 |
| Total Current Assets | 286.24-7.3% | 308.79-3.7% | 320.68-27.9% | 444.50+5.8% | 420.02+250.0% | 119.99+134.7% | 51.12 |
| Net Property, Plant & Equipment | 42.33-12.8% | 48.54-19.4% | 60.19-7.7% | 65.23+95.8% | 33.31+718.4% | 4.07-6.0% | 4.33 |
| Total Investments and Advances | 66.13-53.6% | 142.57+1318.6% | 10.05+2351.2% | 0.41-99.1% | 45.18+14474.2% | 0.31 | 0.00 |
| Deferred Tax Assets | 11.30 | - | - | - | - | - | - |
| Other Assets | 1.45-44.7% | 2.62-40.2% | 4.38-8.2% | 4.77+63.9% | 2.91+546.7% | 0.45+650.0% | 0.06 |
| Total Assets | 407.45-18.9% | 502.53+27.1% | 395.30-23.2% | 514.91+2.7% | 501.42+301.7% | 124.83+124.9% | 55.51 |
| Short Term Debt Incl. Current Port. of LT Debt | 5.07+9.7% | 4.62+16.4% | 3.97+205.4% | 1.30+364.3% | 0.28-68.2% | 0.88+20.5% | 0.73 |
| Accounts Payable | 0.98+108.5% | 0.47-76.5% | 2.00-91.3% | 23.05+392.5% | 4.68+431.8% | 0.88-36.2% | 1.38 |
| Other Current Liabilities | 22.46-14.6% | 26.31+30.3% | 20.19-17.1% | 24.34+13.6% | 21.42+79.5% | 11.93+1764.1% | 0.64 |
| Total Current Liabilities | 28.51-9.2% | 31.39+20.0% | 26.16-46.3% | 48.69+84.6% | 26.38+92.8% | 13.68+397.5% | 2.75 |
| Long Term Debt | 42.07-11.0% | 47.27-8.9% | 51.89-3.5% | 53.79+190.6% | 18.51+777.3% | 2.11-28.7% | 2.96 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 11.30 | - | - | - | - | - | - |
| Other Liabilities | 0.40+11.1% | 0.36-36.8% | 0.570.0% | 0.57 | 0.00-100.0% | 1.61 | 0.00 |
| Total Liabilities | 82.28+4.1% | 79.03+0.5% | 78.61-23.7% | 103.06+129.6% | 44.89+158.0% | 17.40+204.7% | 5.71 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 221.41+249.2% | 63.40 |
| Common Equity | 325.17-23.2% | 423.50+33.7% | 316.69-23.1% | 411.85-9.8% | 456.53 | -113.98 | -13.60 |
| Total Shareholders Equity | 325.17-23.2% | 423.50+33.7% | 316.69-23.1% | 411.85-9.8% | 456.53+325.0% | 107.42+115.7% | 49.80 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 325.17-23.2% | 423.50+33.7% | 316.69-23.1% | 411.85-9.8% | 456.53+325.0% | 107.42+115.7% | 49.80 |
| Total Liabilities & Stockholders Equity | 407.45-18.9% | 502.53+27.1% | 395.30-23.2% | 514.91+2.7% | 501.42+301.7% | 124.83+124.9% | 55.51 |
| Book Value Per Share per share | 1.14-24.0% | 1.50-28.6% | 2.10-23.9% | 2.76-27.9% | 3.83 | -0.96 | -0.11 |
| Tangible Book Value Per Share per share | 1.14-24.0% | 1.50-28.6% | 2.10-23.9% | 2.76-27.9% | 3.83 | -0.96 | -0.11 |
| Full-Time Employees people | 1030.0% | 103-18.3% | 126-2.3% | 129+4.9% | 123+70.8% | 72+140.0% | 30 |
| Price to Book Ratio ratio | 13.63 | 1.58 | 0.95 | 1.43 | 4.06 | 3.80 | - |
| Return on Assets % | -27.37 | -36.01 | -27.48 | -47.78 | -39.21 | -112.74 | - |
| Return on Equity % | -33.27 | -43.68 | -34.33 | -55.92 | -43.54 | -129.32 | - |
| Return on Invested Capital % | -33.91 | -34.34 | -33.93 | -52.14 | -25.84 | -92.81 | -22.82 |
| Quick Ratio ratio | 10.04 | 9.84 | 12.26 | 9.13 | 15.92 | 8.77 | 18.59 |
| Current Ratio ratio | 10.04 | 9.84 | 12.26 | 9.13 | 15.92 | 8.77 | 18.59 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -307.94 | -124.55 | -161.65 | -125.04 | -242.81 | -122.76 | -101.66 | -12.04 |
| Depreciation | 2.89 | 3.11-18.4% | 3.81+2.1% | 3.73+41.3% | 2.64+218.1% | 0.83+53.7% | 0.54+74.2% | 0.31 |
| Other Funds (Non Cash) | 182.12 | 29.31-37.2% | 46.69+142.2% | 19.28-84.1% | 121.11+249.7% | 34.63-46.8% | 65.15 | -0.36 |
| Funds from Operations | -122.92 | -92.13 | -111.15 | -102.03 | -119.05 | -87.31 | -35.97 | -12.09 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 13.82 | -3.33-291.4% | 1.74+114.8% | 0.81-94.9% | 15.79+104.8% | 7.71+134.3% | 3.29+92.4% | 1.71 |
| Cash from Operating Activities | -109.11 | -95.45 | -109.42 | -101.22 | -103.26 | -79.60 | -32.69 | -10.38 |
| Capital Expenditures | -0.13 | -0.13 | -0.06 | -1.77 | -14.55 | -11.21 | -0.95 | -0.60 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.68 | -37.74 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -537.84 | 110.05 | -134.06 | -69.44 | -54.53 | -45.70 | -32.51 | -20.29 |
| Purchase of Investments | -820.26 | -150.97 | -403.38 | -314.39 | -134.33 | -105.81 | -99.20 | -58.89 |
| Sale Or Maturity of Investments | 282.43 | 261.03-3.1% | 269.32+10.0% | 244.94+206.9% | 79.80+32.8% | 60.11-9.9% | 66.69+72.8% | 38.60 |
| Other Uses | -150.00 | -9.50 | -22.50 | -20.00 | -2.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -687.97 | 100.42 | -156.62 | -91.22 | -71.08 | -64.59 | -71.20 | -20.89 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 845.81 | 1.10-99.5% | 240.70+18558.9% | 1.29-98.7% | 98.08-77.7% | 439.40+213.9% | 139.99+730.3% | 16.86 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 845.81 | 1.10-99.5% | 240.70+18558.9% | 1.29-98.7% | 98.08-77.7% | 439.40+213.9% | 139.99+730.3% | 16.86 |
| Proceedsfrom Stock Options | 721.20 | 0.00-100.0% | 239.06 | 0.00-100.0% | 95.25-78.2% | 436.94+219.0% | 136.97+712.4% | 16.86 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 845.81 | 1.10-99.5% | 240.70+18558.9% | 1.29-98.7% | 98.08-77.7% | 439.40+213.9% | 139.99+730.3% | 16.86 |
| Net Change in Cash | 48.73 | 6.07 | -25.34 | -191.14 | -76.27-125.8% | 295.21+717.8% | 36.10 | -14.40 |
| Free Cash Flow | -109.24 | -95.58 | -109.48 | -102.99 | -117.81 | -90.81 | -33.63 | -10.97 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 643.70+123.2% | 268.74-10.6% | 243.79-20.0% | 276.07-7.5% | 288.40-9.6% | 300.66-26.4% | 304.58+2.3% | 298.31-4.5% |
| Short Term Receivables | 5.10+75.9% | 2.50+19.0% | 3.30+32.0% | 2.50+8.7% | 2.90+20.8% | 2.10-4.5% | 2.50+187.4% | 2.30 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 6.40-25.8% | 7.20-8.9% | 6.70-11.0% | 7.66-6.4% | 8.62-2.7% | 7.90+6.9% | 7.53-6.7% | 8.18-1.8% |
| Total Current Assets | 655.19+118.4% | 278.44-10.4% | 253.78-19.3% | 286.24-7.3% | 299.93-9.2% | 310.66-25.7% | 314.62+2.6% | 308.79-3.7% |
| Net Property, Plant & Equipment | 37.99-13.9% | 39.39-13.7% | 40.88-13.2% | 42.33-12.8% | 44.12-11.8% | 45.64-11.4% | 47.11-19.5% | 48.54-19.4% |
| Total Investments and Advances | 304.53+309.4% | 115.94+34.0% | 165.13+54.5% | 66.13-53.6% | 74.39-48.6% | 86.50+65.6% | 106.90+25973.2% | 142.57+1318.6% |
| Deferred Tax Assets | - | - | - | 11.30 | - | - | - | - |
| Other Assets | 1.22-38.1% | 1.28-50.6% | 1.45-44.7% | 1.45-44.7% | 1.97-49.2% | 2.59-34.6% | 2.62-41.3% | 2.62-40.2% |
| Total Assets | 998.94+137.6% | 435.05-2.3% | 461.23-2.1% | 407.45-18.9% | 420.40-20.5% | 445.39-15.3% | 471.24+27.4% | 502.53+27.1% |
| Short Term Debt Incl. Current Port. of LT Debt | 5.59+14.5% | 5.44+15.5% | 5.25+9.6% | 5.07+9.7% | 4.88+9.7% | 4.71+9.8% | 4.79-56.6% | 4.62+16.4% |
| Accounts Payable | 3.83+26.4% | 2.02+21.7% | 2.16-4.4% | 0.98+108.5% | 3.03+26.2% | 1.66-22.4% | 2.26-14.1% | 0.47-76.5% |
| Other Current Liabilities | 34.57+66.2% | 26.11+19.9% | 19.25+4.5% | 22.46-14.6% | 20.80-10.2% | 21.78+18.0% | 18.42+11.1% | 26.31+30.3% |
| Total Current Liabilities | 43.99+53.2% | 33.57+19.3% | 26.66+4.7% | 28.51-9.2% | 28.71-4.4% | 28.15+13.1% | 25.47-15.8% | 31.39+20.0% |
| Long Term Debt | 37.81-12.9% | 39.27-12.2% | 40.70-11.6% | 42.07-11.0% | 43.41-10.5% | 44.71-10.0% | 46.02-9.4% | 47.27-8.9% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 11.30 | - | - | - | - |
| Other Liabilities | 0.39-2.5% | 0.34+30.8% | 0.34+36.0% | 0.40+11.1% | 0.40+17.6% | 0.26+225.0% | 0.25-55.4% | 0.36-36.8% |
| Total Liabilities | 82.20+13.3% | 73.19+0.1% | 67.71-5.6% | 82.28+4.1% | 72.52-8.0% | 73.13-2.0% | 71.74-12.1% | 79.03+0.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 916.74+163.5% | 361.87-2.8% | 393.53-1.5% | 325.17-23.2% | 347.89-22.7% | 372.26-17.5% | 399.50+38.5% | 423.50+33.7% |
| Total Shareholders Equity | 916.74+163.5% | 361.87-2.8% | 393.53-1.5% | 325.17-23.2% | 347.89-22.7% | 372.26-17.5% | 399.50+38.5% | 423.50+33.7% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 916.74+163.5% | 361.87-2.8% | 393.53-1.5% | 325.17-23.2% | 347.89-22.7% | 372.26-17.5% | 399.50+38.5% | 423.50+33.7% |
| Total Liabilities & Stockholders Equity | 998.94+137.6% | 435.05-2.3% | 461.23-2.1% | 407.45-18.9% | 420.40-20.5% | 445.39-15.3% | 471.24+27.4% | 502.53+27.1% |
| Book Value Per Share per share | 2.62+113.0% | 1.16-11.5% | 1.27-9.9% | 1.14-24.0% | 1.23-22.6% | 1.31-20.6% | 1.41-26.2% | 1.50-28.6% |
| Tangible Book Value Per Share per share | 2.62+113.0% | 1.16-11.5% | 1.27-9.9% | 1.14-24.0% | 1.23-22.6% | 1.31-20.6% | 1.41-26.2% | 1.50-28.6% |
| Full-Time Employees people | - | - | - | 1030.0% | - | - | - | 103-18.3% |
| Price to Book Ratio ratio | 13.63 | 14.47 | 14.14 | 3.03 | 1.66 | 0.90 | 0.92 | 1.58 |
| Return on Assets % | -43.39 | -65.25 | -59.42 | -27.37 | -26.90 | -26.42 | -37.47 | -36.01 |
| Return on Equity % | -48.70 | -78.25 | -69.86 | -33.27 | -32.00 | -31.16 | -45.82 | -43.68 |
| Return on Invested Capital % | -5.38 | -10.99 | -42.24 | -7.92 | -7.82 | -8.12 | -6.95 | -6.85 |
| Quick Ratio ratio | 14.89 | 8.29 | 9.52 | 10.04 | 10.45 | 11.04 | 12.35 | 9.84 |
| Current Ratio ratio | 14.89 | 8.29 | 9.52 | 10.04 | 10.45 | 11.04 | 12.35 | 9.84 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -51.33 | -44.08 | -183.44 | -29.09 | -30.61 | -33.88 | -30.97 | -32.23 |
| Depreciation | 0.71-6.6% | 0.72-8.9% | 0.72-12.2% | 0.74-10.8% | 0.76-9.5% | 0.79-30.1% | 0.82-18.0% | 0.83-11.7% |
| Other Funds (Non Cash) | 10.14+46.1% | 9.08-26.8% | 157.67+3233.4% | 5.24-8.2% | 6.94+68.4% | 12.40-61.7% | 4.73+4.9% | 5.71+44.9% |
| Funds from Operations | -40.48 | -34.28 | -25.05 | -23.11 | -22.91 | -20.69 | -25.42 | -25.69 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 7.74+514.3% | 7.01+4281.3% | -2.33 | 1.40+23.9% | 1.26-67.0% | 0.16-69.8% | -6.14 | 1.13+3666.7% |
| Cash from Operating Activities | -32.74 | -27.27 | -27.38 | -21.71 | -21.66 | -20.53 | -31.55 | -24.56 |
| Capital Expenditures | -0.08 | -0.01 | -0.04 | -0.01 | -0.01 | -0.03 | -0.08 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -488.26-1743.4% | 19.50-8.3% | -93.79-373.0% | 24.72+9.3% | 29.71 | 21.27 | 34.35+243.2% | 22.62+388.6% |
| Purchase of Investments | -524.86 | 0.00 | -253.17 | -42.23 | -41.54 | -56.55 | -10.65 | -67.13 |
| Sale Or Maturity of Investments | 36.60-48.6% | 19.50-74.9% | 159.38+254.2% | 66.95-25.4% | 71.25-20.2% | 77.83+114.7% | 45.00-16.7% | 89.75+36.5% |
| Other Uses | 0.00 | 0.00 | -150.00 | 0.00 | -4.00 | -5.50 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -488.34-2000.2% | 19.49+23.8% | -243.83-811.5% | 24.71+9.2% | 25.70 | 15.74 | 34.27+243.7% | 22.62+398.2% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 597.50+1493650.0% | 3.06+580.0% | 244.66+815433.3% | 0.57-28.8% | 0.04-99.8% | 0.45-99.8% | 0.03+50.0% | 0.80+73.9% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 597.50+1493650.0% | 3.06+580.0% | 244.66+815433.3% | 0.57-28.8% | 0.04-99.8% | 0.45-99.8% | 0.03+50.0% | 0.80+73.9% |
| Proceedsfrom Stock Options | 557.25 | -78.35-19687.5% | 242.71 | -0.40 | 0.00-100.0% | 0.40-99.8% | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 597.50+1493650.0% | 3.06+580.0% | 244.66+815433.3% | 0.57-28.8% | 0.04-99.8% | 0.45-99.8% | 0.03-99.6% | 0.80+73.9% |
| Net Change in Cash | 76.42+1768.5% | -4.71 | -26.55-1069.0% | 3.58 | 4.09 | -4.34-104.5% | 2.74 | -1.15 |
| Free Cash Flow | -32.82 | -27.28 | -27.42 | -21.72 | -21.66 | -20.56 | -31.64 | -24.56 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 15.03% | 37.2M | 247.2M | 4.37M |
| 2026-10-15 | 14.95% | 37.0M | 247.2M | 4.38M |
| 2026-09-30 | 14.30% | 35.3M | 247.2M | 4.26M |
| 2026-09-15 | 13.37% | 33.0M | 247.2M | 4.59M |
| 2026-08-31 | 12.68% | 31.2M | 246.4M | 4.78M |
| 2026-08-14 | 12.52% | 30.8M | 246.4M | 4.94M |
| 2026-07-31 | 13.46% | 30.0M | 222.5M | 5.23M |
| 2026-07-15 | 14.74% | 30.8M | 208.8M | 6.94M |
| 2026-06-30 | 17.28% | 32.3M | 187.1M | 6.99M |
| 2026-06-15 | 16.84% | 31.5M | 187.0M | 6.81M |
| 2026-05-29 | 17.06% | 31.9M | 187.0M | 6.72M |
| 2026-05-15 | 16.81% | 31.4M | 187.0M | 6.60M |
| 2026-04-30 | 17.16% | 32.1M | 186.8M | 6.59M |
| 2026-04-15 | 18.19% | 34.0M | 186.8M | 5.42M |
| 2026-03-31 | 16.04% | 29.9M | 186.3M | 6.51M |
| 2026-03-13 | 14.14% | 26.3M | 186.3M | 5.83M |
| 2026-02-27 | 14.71% | 27.3M | 185.6M | 5.33M |
| 2026-02-13 | 15.26% | 28.3M | 185.6M | 5.11M |
| 2026-01-30 | 14.71% | 25.6M | 174.3M | 4.61M |
| 2026-01-15 | 15.45% | 26.6M | 172.4M | 3.56M |
Option chain
Expiry 2026-11-20 · underlying 15.79, quoted 13 Nov 07:18 ET · ATM 16.00
Option quotes 12 Nov 15:47 ET. A date on a row is older than the last session (12 Nov). 33 rows.
Implied move 19.63% into expiry (call 1.400 + put 1.700 = 3.100 on 15.79)
Put/call open interest 0.18 (8,650 puts / 47,502 calls) · Put/call volume 0.18 (57 puts / 310 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 26 Oct | 2.50 | ITM | 12.50 | 14.60 | 12.51 | 0.00 | - | 1 | 0 | 0 | 0.993 | -0.020 | 0.000 |
| put 1 Jan | OTM | 0.00 | 0.05 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.007 | -0.019 | 0.000 | |
| call 29 Oct | 5.00 | ITM | 10.00 | 11.60 | 9.20 | 0.00 | 803.0% +399.4 | 1 | 0 | 0 | 0.987 | -0.020 | 0.001 |
| put 26 Oct | OTM | 0.00 | 0.05 | 0.03 | 0.00 | 700.1% 0.0 | 5 | 0 | 0 | -0.051 | -0.108 | 0.002 | |
| call 8 Oct | 7.50 | ITM | 7.90 | 9.20 | 8.00 | 0.00 | 579.1% +98.0 | 0 | 0 | 0 | 0.921 | -0.106 | 0.003 |
| put 1 Jan | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 481.1% 0.0 | 0 | 0 | 0 | -0.079 | -0.105 | 0.003 | |
| call 1 Jan | 9.00 | ITM | 5.90 | 7.70 | 0.00 | 0.00 | 467.3% +82.1 | 0 | 0 | 0 | 0.899 | -0.101 | 0.004 |
| put 1 Jan | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 385.3% 0.0 | 0 | 0 | 0 | -0.101 | -0.100 | 0.004 | |
| call 20 Oct | 10.00 | ITM | 5.40 | 6.70 | 4.25 | 0.00 | 403.4% +73.5 | 34 | 0 | 0 | 0.882 | -0.097 | 0.005 |
| put 6 Nov | OTM | 0.00 | 0.55 | 0.05 | 0.00 | 329.9% 0.0 | 2,411 | 0 | 0 | -0.118 | -0.096 | 0.005 | |
| call 1 Jan | 11.00 | ITM | 4.70 | 6.90 | 0.00 | 0.00 | 507.6% +228.3 | 0 | 0 | 0 | 0.862 | -0.092 | 0.005 |
| put 1 Jan | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 279.3% 0.0 | 0 | 0 | 0 | -0.138 | -0.091 | 0.005 | |
| call 10 Nov | 12.50 | ITM | 3.40 | 4.20 | 3.40 | 0.00 | 265.4% +47.7 | 58 | 0 | 0 | 0.814 | -0.087 | 0.006 |
| put | OTM | 0.15 | 0.60 | 0.34 | +0.10 | 217.7% 0.0 | 3,640 | 2 | 1 | -0.186 | -0.086 | 0.006 | |
| call 6 Nov | 14.00 | ITM | 1.20 | 3.20 | 1.30 | 0.00 | 253.3% +38.3 | 1 | 0 | 0 | 0.705 | -0.110 | 0.008 |
| put | OTM | 0.50 | 1.10 | 0.60 | +0.15 | 215.0% 0.0 | 7 | 1 | 1 | -0.295 | -0.109 | 0.008 | |
| call | 15.00 | ITM | 1.65 | 2.25 | 2.10 | -0.85 | 203.9% +4.9 | 9,640 | 15 | 1 | 0.627 | -0.112 | 0.009 |
| put | OTM | 0.75 | 1.40 | 1.00 | +0.13 | 197.4% -1.6 | 2,394 | 51 | 42 | -0.373 | -0.110 | 0.009 | |
| call | 16.00 | ATM | 1.15 | 1.65 | 1.58 | -0.47 | 189.3% -6.8 | 82 | 60 | 1 | 0.539 | -0.116 | 0.009 |
| put | ATM | 1.40 | 2.00 | 1.58 | +0.43 | 204.9% +8.9 | 117 | 3 | 1 | -0.461 | -0.114 | 0.009 | |
| call | 17.50 | OTM | 0.50 | 1.30 | 0.90 | -0.50 | 210.9% 0.0 | 29,165 | 68 | 1 | 0.430 | -0.123 | 0.009 |
| put 11 Nov | ITM | 2.35 | 3.10 | 1.88 | 0.00 | 221.4% +10.5 | 73 | 0 | 0 | -0.570 | -0.121 | 0.009 | |
| call | 19.00 | OTM | 0.30 | 1.20 | 0.55 | -0.35 | 246.1% 0.0 | 180 | 8 | 8 | 0.370 | -0.138 | 0.009 |
| put 1 Jan | ITM | 2.80 | 5.10 | 0.00 | 0.00 | 323.9% +77.8 | 0 | 0 | 0 | -0.630 | -0.135 | 0.009 | |
| call | 20.00 | OTM | 0.10 | 0.60 | 0.41 | -0.24 | 198.0% 0.0 | 847 | 128 | 2 | 0.252 | -0.094 | 0.007 |
| put 9 Oct | ITM | 4.10 | 5.20 | 5.00 | 0.00 | 248.5% +50.5 | 2 | 0 | 0 | -0.748 | -0.091 | 0.007 | |
| call | 21.00 | OTM | 0.05 | 0.65 | 0.35 | -0.15 | 219.8% 0.0 | 14 | 14 | 1 | 0.235 | -0.100 | 0.007 |
| put 1 Jan | ITM | 3.70 | 6.80 | 0.00 | 0.00 | 342.9% +123.1 | 0 | 0 | 0 | -0.765 | -0.098 | 0.007 | |
| call | 22.50 | OTM | 0.00 | 0.40 | 0.25 | -0.15 | 217.5% 0.0 | 7,402 | 17 | 1 | 0.171 | -0.082 | 0.006 |
| put 30 Sep | ITM | 6.00 | 8.30 | 8.20 | 0.00 | 376.1% +158.6 | 1 | 0 | 0 | -0.829 | -0.079 | 0.006 | |
| call 1 Jan | 24.00 | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 242.3% 0.0 | 0 | 0 | 0 | 0.158 | -0.087 | 0.006 |
| put 1 Jan | ITM | 7.50 | 9.00 | 0.00 | 0.00 | 304.6% +62.4 | 0 | 0 | 0 | -0.842 | -0.084 | 0.006 | |
| call 5 Nov | 25.00 | OTM | 0.00 | 0.55 | 0.08 | 0.00 | 257.4% 0.0 | 76 | 0 | 0 | 0.152 | -0.089 | 0.005 |
| put 1 Jan | ITM | 8.40 | 10.60 | 0.00 | 0.00 | 399.7% +172.7 | 0 | 0 | 0 | -0.888 | -0.061 | 0.004 | |
| call 1 Jan | 26.00 | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 276.6% 0.0 | 0 | 0 | 0 | 0.158 | -0.099 | 0.006 |
| put 1 Jan | ITM | 9.40 | 11.70 | 0.00 | 0.00 | 428.7% +188.4 | 0 | 0 | 0 | -0.892 | -0.063 | 0.004 | |
| call 1 Jan | 27.00 | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 290.2% 0.0 | 0 | 0 | 0 | 0.152 | -0.101 | 0.006 |
| put 1 Jan | ITM | 10.40 | 12.20 | 0.00 | 0.00 | 380.3% +95.2 | 0 | 0 | 0 | -0.859 | -0.091 | 0.005 | |
| call 1 Jan | 28.00 | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 303.1% 0.0 | 0 | 0 | 0 | 0.148 | -0.104 | 0.005 |
| put 1 Jan | ITM | 10.90 | 13.20 | 0.00 | 0.00 | 394.7% +96.9 | 0 | 0 | 0 | -0.863 | -0.093 | 0.005 | |
| call 1 Jan | 29.00 | OTM | 0.00 | 0.55 | 0.00 | 0.00 | 315.3% 0.0 | 0 | 0 | 0 | 0.144 | -0.106 | 0.005 |
| put 1 Jan | ITM | 11.90 | 14.20 | 0.00 | 0.00 | 408.2% +131.8 | 0 | 0 | 0 | -0.903 | -0.067 | 0.004 | |
| call 23 Sep | 30.00 | OTM | 0.00 | 0.55 | 0.15 | 0.00 | 321.5% 0.0 | 1 | 0 | 0 | 0.130 | -0.100 | 0.005 |
| put 1 Jan | ITM | 12.90 | 15.20 | 0.00 | 0.00 | 421.2% +134.0 | 0 | 0 | 0 | -0.905 | -0.068 | 0.004 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 8-K | Current report | 2026-11-12 | SEC |
| 2026-11-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-10-16 | 8-K | Current report | 2026-10-15 | SEC |
| 2026-10-15 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-15 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-24 | 8-K | Current report | 2026-08-24 | SEC |
| 2026-08-17 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-10 | SEC |
| 2026-08-12 | 3 | Initial statement of beneficial ownership of securities | 2026-08-10 | SEC |
| 2026-08-11 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-11 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-11 | 8-K | Current report | 2026-08-11 | SEC |
| 2026-08-10 | 8-K | Current report | 2026-08-10 | SEC |
| 2026-07-21 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-14 | 8-K | Current report | 2026-07-13 | SEC |
| 2026-07-14 | 424B5 | SEC | ||
| 2026-07-13 | 424B5 | SEC | ||
| 2026-07-13 | 8-K | Current report | 2026-07-13 | SEC |
| 2026-07-13 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | SEC | |
| 2026-07-01 | 8-K | Current report | 2026-06-26 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
| 2026-06-15 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G/A | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 1.31M | 1 |
| 2026-03 | 0 | 0 | 300.76K | 1 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 670.81K | 1 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Frazier Life Sciences Management, L.P. | 8.03% |
| T. Rowe Price Investment Management, Inc. | 6.81% |
| BlackRock, Inc. | 6.80% |
| RTW INVESTMENTS, LP | 5.77% |
| Venrock Adviser, LLC | 5.75% |
| STATE STREET CORP | 3.95% |
| Logos Global Management LP | 3.91% |
| Siren, L.L.C. | 3.77% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.67% |
| Paradigm Biocapital Advisors LP | 3.07% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.70% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.39% |
| T. Rowe Price Capital Appreciation Fund | 2.24% |
| iShares Russell 2000 ETF | 1.65% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.07% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.88% |
| T. Rowe Price Health Sciences Fund, Inc. | 0.83% |
| Select Biotechnology Portfolio | 0.71% |
| Fidelity Small Cap Index Fund | 0.69% |
| T. Rowe Price Institutional Small-Cap Stock Fund | 0.57% |
OakChart. ERAS. Cached 15 minutes. Terms